[On the problem of the toxic effect of trivalent antimony preparations].
D000410:Alanine Transaminase; D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001219:Aspartate Aminotransferases; D001557:Benzenesulfonates / Q000633:toxicity; D001798:Blood Proteins / Q000032:analysis; D001799:Blood Sedimentation; D002490:Central Nervous System / Q000187:drug effects; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D004562:Electrocardiography; D004569:Electroencephalography; D004586:Electrophoresis; D006321:Heart / Q000187:drug effects; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008099:Liver / Q000187:drug effects; D009336:Necrosis / Q000139:chemically induced; D012552:Schistosomiasis / Q000188:drug therapy*; D013268:Stimulation, Chemical
D000981:Antiprotozoal Agents; D001557:Benzenesulfonates; D001798:Blood Proteins; D002556:Cerebrospinal Fluid Proteins; D006454:Hemoglobins; D000965:Antimony; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
Zur Frage der toxischen Wirkung dreiwertiger Antimonpräparate.